
Tirosina Quinase/Adaptador
Os inibidores de tirosina quinase e adaptadores são compostos que têm como alvo as tirosina quinases e suas proteínas adaptadoras associadas, que desempenham papéis fundamentais na sinalização celular, crescimento e diferenciação. Esses inibidores são ferramentas essenciais na pesquisa sobre o câncer, pois muitas tirosina quinases estão envolvidas nas vias de sinalização que impulsionam o crescimento e a metástase dos tumores. Ao inibir as tirosina quinases, esses compostos podem bloquear cascatas de sinalização críticas, oferecendo potenciais estratégias terapêuticas para vários tipos de câncer e outras doenças que envolvem sinalização celular anormal. Na CymitQuimica, oferecemos uma ampla gama de inibidores de tirosina quinase e adaptadores de alta qualidade para apoiar sua pesquisa em oncologia, biologia molecular e desenvolvimento de terapias direcionadas.
Subcategorias de "Tirosina Quinase/Adaptador"
- ALK(112 produtos)
- CSF-1R(42 produtos)
- EGFR(572 produtos)
- Receptor de Efrina(23 produtos)
- FLT(93 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- HER(5 produtos)
- Hck(3 produtos)
- IGF-1R(87 produtos)
- PDGFR(126 produtos)
- PYK2(7 produtos)
- Src(79 produtos)
- Receptor TAM(32 produtos)
- Tie-2(20 produtos)
- Receptor TrK(59 produtos)
- Tirosina Quinases(26 produtos)
- VEGFR(268 produtos)
- c-Fms(108 produtos)
- c-Kit(101 produtos)
- c-Met/HGFR(128 produtos)
- c-RET(51 produtos)
Exibir 13 mais subcategorias
Foram encontrados 1372 produtos de "Tirosina Quinase/Adaptador"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
IMPDH2-IN-4
<p>IMPDH2-IN-4 (compound 2d) is a Mycophenolic acid analog and a selective IMPDH2 inhibitor with a Ki of 1.8 μM. It exhibits potent cytotoxic activity against osteosarcoma cancer cell lines. Additionally, IMPDH2-IN-4 demonstrates high affinity for VEGFR-2, CDK2, and IMPDH.</p>Fórmula:C35H34O6SiCor e Forma:SolidPeso molecular:578.73GIP (1-30) amide, porcine TFA
<p>GIP (1-30) amide, porcine TFA: a full GIP receptor agonist, similar to natural GIP(1-42), stimulates insulin, mildly inhibits gastric acid.</p>Cor e Forma:LiquidLeucettine L41
CAS:<p>Leucettine L41 (LeucettineL41) is an inhibitor of DYRKs/CLKs, preferentially targeting DYRK1A, and inhibits DYRK2.</p>Fórmula:C17H13N3O3Pureza:99.08%Cor e Forma:SolidPeso molecular:307.3Oritinib
CAS:<p>Oritinib (SH-1028) is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (</p>Fórmula:C31H37N7O2Pureza:99.62%Cor e Forma:SoildPeso molecular:539.67Mecbotamab vedotin
CAS:<p>Mecbotamab vedotin (BA301) is an inhibitory IgG1 antibody that targets human tyrosine kinase receptor AXL and the humanized murine monoclonal BA301 γ1 chain. It can be utilized in the preparation of immunoconjugates for research into cancers expressing the Axl type.</p>Cor e Forma:LiquidLCB 03-0110 dihydrochloride
CAS:<p>LCB 03-0110 Dihydrochloride is a potent inhibitor of the c-Src kinase (IC50 = 1.3 nM) and tyrosine kinases in the BTK and SYK family, as well as in the DDR2</p>Fórmula:C24H25Cl2N3O2SPureza:99.9%Cor e Forma:SoildPeso molecular:490.45CLK1-IN-3
CAS:<p>Clk1-in-3 is a + selective and highly potent sexual Clk1 inhibitor with an IC50 of 5 nM and 300 pairs higher affinity than Dyrk1A.</p>Fórmula:C24H23FN6OPureza:98.46% - 99.76%Cor e Forma:SoildPeso molecular:430.48BMS-599626
CAS:<p>BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.</p>Fórmula:C27H27FN8O3Pureza:98.73%Cor e Forma:SolidPeso molecular:530.55Caffeic acid-pYEEIE
CAS:<p>Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,).</p>Fórmula:C39H50N5O19PPureza:98%Cor e Forma:SolidPeso molecular:923.82Anticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Cor e Forma:Odour SolidCalcineurin substrate
CAS:<p>Calcineurin Substrate is a Peptide from the regulatory RII subunit of cAMP-dependent protein kinase.</p>Fórmula:C92H150N28O29Pureza:98%Cor e Forma:SolidPeso molecular:2112.35Cetuximab MMAE
<p>Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.</p>Cor e Forma:LiquidPeso molecular:150 kDaZIGIR
<p>ZIGIR enables insulin-based sorting of pure alpha and beta cells, revealing zinc(II) in human delta cell granules.</p>Fórmula:C39H40N6O3Pureza:98.34% - 99.32%Cor e Forma:SolidPeso molecular:640.77JAK 3 inhibitor IV
CAS:<p>JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to</p>Fórmula:C16H19NOPureza:98%Cor e Forma:SolidPeso molecular:241.33Antiproliferative agent-57
<p>Antiproliferative agent-57 (compound M2) is a tumor angiogenesis inhibitor that suppresses VEGF secretion in SiHa cells under hypoxic conditions without inducing cytotoxicity (IC50=0.68 μM). It modulates the PI3K/AKT/mTOR and MAPK signaling pathways in tumor cells, thereby inhibiting the expression of HIF-1α and VEGF within tumor tissues.</p>Cor e Forma:Odour SolidJBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Fórmula:C33H30F4N4O5SCor e Forma:SolidPeso molecular:670.67KN1022
CAS:<p>KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.</p>Fórmula:C21H22N6O5Pureza:99.68%Cor e Forma:SoildPeso molecular:438.44EGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Fórmula:C27H31N3O2Cor e Forma:SolidPeso molecular:429.24163(Pro3) GIP, human
CAS:<p>(Pro3) GIP, human: stable hGIPR full agonist, high affinity (Ki/Kd=0.90nM), for obesity-related diabetes research.</p>Fórmula:C226H338N60O64SCor e Forma:SolidPeso molecular:4951.53PROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Fórmula:C58H72ClFN12O8SCor e Forma:SolidPeso molecular:1151.78

